Rapid SUBLOCADE Induction Shows Superior Patient Retention in Opioid Use Disorder Treatment
核心洞察
A multicenter clinical trial published in JAMA Network Open demonstrates that rapid induction with SUBLOCADE using a single 4 mg oral buprenorphine dose followed by same-day injection improves patient retention compared to standard protocols.
The rapid induction approach was particularly effective among fentanyl-positive participants, addressing a critical need for flexible treatment strategies in the current fentanyl era.
The study showed that administering the second SUBLOCADE injection just one week after the first was well tolerated in both treatment arms, supporting more agile patient-centered treatment models.
Indivior PLC has published compelling results from a multicenter, open-label clinical trial in JAMA Network Open demonstrating that rapid induction with SUBLOCADE (buprenorphine extended-release injection) significantly improves treatment retention rates for patients with moderate-to-severe opioid use disorder (OUD), particularly those using fentanyl.
Enhanced Treatment Retention with Rapid Protocol
The study evaluated two approaches for initiating SUBLOCADE treatment in individuals meeting criteria for moderate-to-severe OUD who engage in high-risk opioid use, including injection use, high-dose consumption, or fentanyl use. The rapid induction protocol involved administration of a single 4 mg oral buprenorphine dose followed by a same-day SUBLOCADE injection, compared to standard induction requiring at least seven days of oral buprenorphine dose adjustments prior to the first injection.
Results showed that rapid induction led to higher retention at the second injection compared to standard induction across the full study population. These benefits were especially pronounced among fentanyl-positive participants, addressing the clinically relevant outcome of keeping patients engaged with treatment after induction.
Safety Profile and Tolerability
The trial demonstrated that rapid induction was well tolerated, with a safety profile comparable to standard induction up to the second injection. A similar proportion of participants experienced adverse events up to injection two in both treatment arms. Additionally, administering the second SUBLOCADE injection just one week after the first was well tolerated in both treatment groups, reinforcing the potential for more agile and patient-centered treatment approaches.
"This study represents a pivotal advancement for both patients and clinicians confronting opioid use disorder in the fentanyl era," said Christian Heidbreder, Ph.D., Chief Scientific Officer at Indivior. "The demonstration that rapid, same-day induction onto SUBLOCADE is not only effective but also well tolerated is opening a critical window of opportunity to keep high-risk patients with moderate-to-severe OUD engaged in care during their most vulnerable early weeks of treatment."
Clinical Implications for Fentanyl Era Treatment
The findings are particularly significant given the current landscape of opioid use disorder treatment, where fentanyl use presents unique challenges for patient retention and treatment engagement. The study's focus on high-risk populations, including those with injection use patterns and fentanyl exposure, addresses a critical gap in treatment protocols for these vulnerable patient groups.
The research supports a shift toward more patient-centered and flexible opioid treatment approaches, potentially improving outcomes during the critical early weeks of treatment when patients are most vulnerable to discontinuation.
Study Limitations and Design
Study limitations include its open-label design, which could introduce some reporting bias, although researchers noted there was no evidence of patient and provider preference for either treatment strategy. The multicenter design and focus on clinically relevant retention outcomes strengthen the study's applicability to real-world treatment settings.
SUBLOCADE is indicated for the treatment of moderate to severe opioid use disorder in patients who have initiated treatment with a single dose of a transmucosal buprenorphine product or who are already being treated with buprenorphine, and should be used as part of a complete treatment plan that includes counseling and psychosocial support.